Kiri Granger
Co-Founder & Chief Scientific Officer Monument Therapeutics
With 10 years of industry experience, Kiri is a highly regarded expert in the CNS field, particularly in schizophrenia. During her role as Director of Neuroscience at Cambridge Cognition, she was lead scientist on over 100 clinical trial programs and gained recognition for her innovative strategies that successfully demonstrated the efficacy of compounds following negative trial results. During her PhD at the University of Nottingham, Kiri developed the biomarker that is now integral to Monument’s schizophrenia program, helping to establish the company’s precision medicine approach. She is an inventor on multiple patents and serves as Assistant Professor in the Department of Psychology at the University of Nottingham, reflecting her commitment to advancing research in neuroscience.
Seminars
- Discover how objective digital cognitive biomarkers can identify biologically distinct patient subgroups, reducing the heterogeneity that has historically contributed to schizophrenia trial failures and enabling precision medicine approaches in psychiatry
- Explore how multimodal biomarkers can be integrated across the clinical development pathway, from patient selection and experimental medicine through to objective efficacy endpoints, to generate stronger proof-of-mechanism and improve decision-making
- Learn from Monument Therapeutics’ translational development strategy for MT1988, including early regulatory engagement around digital biomarker validation and the challenges of moving novel digital endpoints towards broader clinical adoption
